Market closedNon-fractional

Atossa Therapeutics/ATOS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Atossa Therapeutics

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Ticker

ATOS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Seattle, United States

Employees

12

ATOS Metrics

BasicAdvanced
$147M
Market cap
-
P/E ratio
-$0.24
EPS
1.21
Beta
-
Dividend rate
$147M
1.21
16.339
15.758
-18.85%
-29.84%
1.71
1.71
-7.895
5.06%
-30.80%

What the Analysts think about ATOS

Analyst Ratings

Majority rating from 4 analysts.
Buy

ATOS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$5.8M
-24.68%
Profit margin
0.00%
NaN%

ATOS Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 25.00%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.08
-$0.05
-$0.09
-$0.05
-
Expected
-$0.06
-$0.07
-$0.06
-$0.07
-$0.06
Surprise
33.33%
-28.57%
58.82%
-25.00%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Atossa Therapeutics stock?

Atossa Therapeutics (ATOS) has a market cap of $147M as of July 06, 2024.

What is the P/E ratio for Atossa Therapeutics stock?

The price to earnings (P/E) ratio for Atossa Therapeutics (ATOS) stock is 0 as of July 06, 2024.

Does Atossa Therapeutics stock pay dividends?

No, Atossa Therapeutics (ATOS) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Atossa Therapeutics dividend payment date?

Atossa Therapeutics (ATOS) stock does not pay dividends to its shareholders.

What is the beta indicator for Atossa Therapeutics?

Atossa Therapeutics (ATOS) has a beta rating of 1.21. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Atossa Therapeutics stock

Buy or sell Atossa Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing